HKG Epitherapeutics Inc. was founded in 2016 by Prof. Moshe Szyf, a world pioneer in the exciting and rapidly emerging science of Epigenetics.
A Canadian company, dedicated to harnessing the untapped power and possibilities of Epigenetics (with its research and diagnostic lab in Hong Kong), HKG Epithehrapeutics is planning to expand operations by establishing “next generation” genetic diagnostic labs in several countries.
With an emphasis on the evolving markets in Euro-Asia and our immediate focus on tests, prevention and early treatment for common diseases, our mission is to positively impact the healthcare, well-being and quality of life for large populations of people, worldwide.
Simply stated, the science of Epigenetics centers on DNA Methylation (a simple biochemical process) that changes a mark on your DNA when cancer or other catastrophic diseases may develop.
While the company is new, Szyf’s three decades of ground-breaking research and cutting-edge innovations in Epigenetics — how it occurs and how it is passed from generation to generation — has already disrupted medical science with its potential to detect, diagnose, prevent or cure diseases.
HKG Epitherapeutics believes the ability to measure and diagnose these changes in DNA will not only revolutionize the impact on fighting disease but on regulating our critical cardiovascular, neurological, reproductive, and detoxification systems as well.
We believe that integrating our novel diagnostics into these developing markets will greatly affect the quality of health care for the people of these countries. We are interested in building diagnostic licensing partnerships in this area, as they become available.
We invite you to contact us for more information. Join our mission to be a major force in the explosive new science of Epigenetics by becoming a partner and an influencer in global healthcare.